Kadmon Holdings, Inc. (KDMN)
(Delayed Data from NYSE)
$2.33 USD
+0.08 (3.56%)
Updated May 3, 2019 04:02 PM ET
After-Market: $2.32 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[KDMN]
Reports for Purchase
Showing records 21 - 36 ( 36 total )
Industry: Medical - Biomedical and Genetics
Positive KOL Feedback Ahead of KD025 Pivotal Study Topline
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
New Data Point at EHA Strengthens the Data Package of KD025
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
FDA Dialogue Continues to Support KD025''s Potential in cGVHD; Reit Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
Steady Progress With Pivotal Study on Track to Readout in 2H19
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
Strong Phase 2 Data at ASH Should Help Derisk the Ongoing Pivotal Study
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
Thoughts on KD025 in cGVHD Ahead of ASH; Reit Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Unclassified
KD025 Is on Track to Advance; Reit Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Unclassified
Progress on Multiple Fronts; Reit Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Unclassified
Awaiting a Year of Execution to Advance Optionality Thesis for KD025; Reit Buy and $25PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Unclassified
IPF Data Further Support Inherent Optionality Thesis; Reit Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Unclassified
Updated Data at ASH Reinforces Our Bullish View on KD025; Reit Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Unclassified
Remain Bullish Ahead of Additional KD025 in cGVHD Data at ASH; Reit Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Unclassified
NT GvHD Update Likely to Accelerate Investor Re-Engagement; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Unclassified
Recent industry deal highlights value trends in autoimmune therapeutics
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Unclassified
Clinical Pipeline Optionality Unchanged, But Now at a Discount
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Unclassified
We are initiating coverage with a Buy rating and a $25 price target.
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A